small cell lung cancer cell lines Search Results


human lung cancer cell line  (ATCC)
96
ATCC human lung cancer cell line
Human Lung Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lung cancer cell line/product/ATCC
Average 96 stars, based on 1 article reviews
human lung cancer cell line - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
non small cell lung cancer nsclc adenocarcinoma  (AMS Biotechnology)
94
AMS Biotechnology non small cell lung cancer nsclc adenocarcinoma
Non Small Cell Lung Cancer Nsclc Adenocarcinoma, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non small cell lung cancer nsclc adenocarcinoma/product/AMS Biotechnology
Average 94 stars, based on 1 article reviews
non small cell lung cancer nsclc adenocarcinoma - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
nci h1975 cells genecopoeia sl003 experimental models  (Genecopoeia)
95
Genecopoeia nci h1975 cells genecopoeia sl003 experimental models
Nci H1975 Cells Genecopoeia Sl003 Experimental Models, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nci h1975 cells genecopoeia sl003 experimental models/product/Genecopoeia
Average 95 stars, based on 1 article reviews
nci h1975 cells genecopoeia sl003 experimental models - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
lc1921c  (AMS Biotechnology)
96
AMS Biotechnology lc1921c
Summary of butyrophilin 1A1 staining results in tissue microarray scores for patients with different solid and hematological tumor types
Lc1921c, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lc1921c/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
lc1921c - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
small cell lung cancer sclc  (AMS Biotechnology)
94
AMS Biotechnology small cell lung cancer sclc
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
Small Cell Lung Cancer Sclc, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small cell lung cancer sclc/product/AMS Biotechnology
Average 94 stars, based on 1 article reviews
small cell lung cancer sclc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
peptide h3  (Cell Signaling Technology Inc)
92
Cell Signaling Technology Inc peptide h3
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
Peptide H3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptide h3/product/Cell Signaling Technology Inc
Average 92 stars, based on 1 article reviews
peptide h3 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
small cell lung cancer  (TaKaRa)
94
TaKaRa small cell lung cancer
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
Small Cell Lung Cancer, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small cell lung cancer/product/TaKaRa
Average 94 stars, based on 1 article reviews
small cell lung cancer - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
h460 large cell lung cancer cell line  (Eisai Inc)
90
Eisai Inc h460 large cell lung cancer cell line
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
H460 Large Cell Lung Cancer Cell Line, supplied by Eisai Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h460 large cell lung cancer cell line/product/Eisai Inc
Average 90 stars, based on 1 article reviews
h460 large cell lung cancer cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
small cell lung cancer  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare small cell lung cancer
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
Small Cell Lung Cancer, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small cell lung cancer/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
small cell lung cancer - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nsclc  (Takeda)
90
Takeda nsclc
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
Nsclc, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nsclc/product/Takeda
Average 90 stars, based on 1 article reviews
nsclc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
non-small cell lung cancer cell  (Tanabe)
90
Tanabe non-small cell lung cancer cell
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
Non Small Cell Lung Cancer Cell, supplied by Tanabe, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non-small cell lung cancer cell/product/Tanabe
Average 90 stars, based on 1 article reviews
non-small cell lung cancer cell - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
a549 non-small-cell lung cancer cells  (Jingzhou Natural Astaxanthin)
90
Jingzhou Natural Astaxanthin a549 non-small-cell lung cancer cells
TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, <t>immunohistochemistry;</t> <t>NSCLC,</t> non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; <t>SCLC,</t> small cell lung carcinoma; TNBC, triple-negative breast carcinoma.
A549 Non Small Cell Lung Cancer Cells, supplied by Jingzhou Natural Astaxanthin, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 non-small-cell lung cancer cells/product/Jingzhou Natural Astaxanthin
Average 90 stars, based on 1 article reviews
a549 non-small-cell lung cancer cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Summary of butyrophilin 1A1 staining results in tissue microarray scores for patients with different solid and hematological tumor types

Journal: Journal for Immunotherapy of Cancer

Article Title: BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1

doi: 10.1136/jitc-2023-008303

Figure Lengend Snippet: Summary of butyrophilin 1A1 staining results in tissue microarray scores for patients with different solid and hematological tumor types

Article Snippet: Squamous non-small cell lung cancer , AMSBIO LC1921c , 84% , 10% , 6%.

Techniques: Staining, Microarray

TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; SCLC, small cell lung carcinoma; TNBC, triple-negative breast carcinoma.

Journal: Molecular Cancer Therapeutics

Article Title: OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models

doi: 10.1158/1535-7163.MCT-24-0588

Figure Lengend Snippet: TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; SCLC, small cell lung carcinoma; TNBC, triple-negative breast carcinoma.

Article Snippet: Up to 448 formalin-fixed, paraffin-embedded human late-stage tumor tissue samples, representing 19 cancer types [bladder cancer, cervical adenocarcinoma, cervical squamous cell carcinoma (SCC), colorectal cancer, endometrial cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck cancer, hormone receptor-positive (HR + ) breast cancer, human epidermal growth factor receptor 2-positive (HER2 + ) breast cancer, non-small cell lung cancer (NSCLC) adenocarcinoma, NSCLC SCC, ovarian adenocarcinoma, pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC)], were purchased from AMS Biotechnology.

Techniques: Expressing, Membrane, Immunohistochemistry